NORTHWEST BIOTHERAPEUTICS INC (NWBO) Form 10-Q — May 15, 2026
Northwest Biotherapeutics reported a net loss of $3.1 million for the first quarter of 2026, driven by $4.9 million in R&D and $6.5 million in G&A expenses, partially offset by a $2.25 million litigation settlement gain and non-cash fair value adjustments. The company generated only $494,000 in revenue, primarily from research services, while burning through cash reserves that now stand at just $1.8 million against total liabilities of $118 million. Management explicitly disclosed substantial doubt about the company’s ability to continue as a going concern, citing insufficient liquidity to fund operations, capital expenditures, and working capital requirements for the next year.
Key figures
- Eps
- 0
- Revenue
- 494000
- Total Debt
- 59429000
- Cash Position
- 1786000
- Shares Outstanding
- 1643343757
- G And AExpense
- 6536000
- R And DExpense
- 4858000
- Settlement Gain
- 2250000
- Interest Expense
- 2346000
- Total Liabilities
- 118111000
- Debt Extinguishment Loss
- 4756000
- Convertible Notes Fair Value
- 38341000
Price after filing
Close on the filing date to close N calendar days later (from $0.25). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.